Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: Anti-amyloid-β antibody attenuates pathologies in an age-related macular degeneration mouse model

84Citations
Citations of this article
78Readers
Mendeley users who have this article in their library.

Abstract

Age-related macular degeneration (AMD) is a late-onset, neurodegenerative retinal disease that shares several clinical and pathological features with Alzheimer's disease (AD) including extracellular deposits containing amyloid-β (Aβ) peptides. Immunotherapy targeting the Aβ protein has been investigated as a potential treatment for AD. Here, we present the rationale for extending this approach to treat AMD. We tested an anti-Aβ antibody administered systemically in a mouse model of AMD. Histological and functional measurements in treated animals compared to controls showed that following immunotherapy, the amounts of Aβ in the retina and brain were decreased and the ERG deficits in the retina were attenuated. These data support the hypothesis that Aβ is a therapeutic target for AMD. © 2007 Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Ding, J. D., Lin, J., Mace, B. E., Herrmann, R., Sullivan, P., & Bowes Rickman, C. (2008). Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: Anti-amyloid-β antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Research, 48(3), 339–345. https://doi.org/10.1016/j.visres.2007.07.025

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free